2003
Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano D. Longitudinal Patterns of Drug Injection Behavior in the ALIVE Study Cohort,1988–2000: Description and Determinants. American Journal Of Epidemiology 2003, 158: 695-704. PMID: 14507606, DOI: 10.1093/aje/kwg209.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug injection behaviorDrug usersIntravenous Experience (ALIVE) studyDrug treatment programsHistory of incarcerationLogistic regression modelsALIVE studySemiannual visitsMultinomial logistic regression modelsBaseline factorsChronic diseasesDrug injectionRecent overdoseCessation attemptsDrug use transitionsDrug injectorsCommunity outreach effortsLongitudinal patternsHigh mortalityEarly determinantsYounger ageTreatment programInjection behaviorStudy period
1999
Direct Comparison of Time to AIDS and Infectious Disease Death Between HIV Seroconverter Injection Drug Users in Italy and the United States: Results From the ALIVE and ISS Studies
Pezzotti P, Galai N, Vlahov D, Rezza G, Lyles C, Astemborski J. Direct Comparison of Time to AIDS and Infectious Disease Death Between HIV Seroconverter Injection Drug Users in Italy and the United States: Results From the ALIVE and ISS Studies. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 275-282. PMID: 10077177, DOI: 10.1097/00042560-199903010-00010.Peer-Reviewed Original ResearchConceptsInjection drug usersDate of seroconversionYear of seroconversionMedian timeRelative hazardGroups of IDUsDrug usersInfectious diseasesCohort of IDUsFirst positive HIV testClinic-based cohortSimilar median timeHIV disease progressionProspective cohort studyPositive HIV testInjection drug useCommunity-based cohortHIV-positive individualsInfectious disease deathsTime of seroconversionDrug use characteristicsTerms of ageProportion of womenALIVE studyCohort study
1998
Socially desirable response tendency as a correlate of accuracy of self‐reported HIV serostatus for HIV seropositive injection drug users
Latkin C, Vlahov D. Socially desirable response tendency as a correlate of accuracy of self‐reported HIV serostatus for HIV seropositive injection drug users. Addiction 1998, 93: 1191-1197. PMID: 9813900, DOI: 10.1046/j.1360-0443.1998.93811917.x.Peer-Reviewed Original ResearchConceptsSelf-reported HIV serostatusSocial desirabilityInjection drug usersCorrelates of accuracyDesirable response tendenciesHIV serostatusDrug usersResponse tendenciesDesirable respondingHIV-seronegative participantsALIVE studyPredictive validityHIV-seropositive injection drug usersActive injection drug usersLongitudinal studySeropositive injection drug usersPositive predictive value 97Higher scoresHIV-seropositive participantsHIV prevention studyQuestionable validityNegative predictive valueParticipantsSeronegative participantsSeropositive participants
1996
The long‐term outcome of a personal network‐oriented HIV prevention intervention for injection drug users: The SAFE study
Latkin C, Mandell W, Vlahov D, Oziemkowska M, Celentano D. The long‐term outcome of a personal network‐oriented HIV prevention intervention for injection drug users: The SAFE study. American Journal Of Community Psychology 1996, 24: 341-364. PMID: 8864208, DOI: 10.1007/bf02512026.Peer-Reviewed Original ResearchConceptsNeedle sharingSocial influence processesHuman immunodeficiency virus (HIV) risk behaviorsNetwork-oriented interventionMultiple logistic regression modelFrequent needle sharingSharing of cookersHIV-seronegative participantsLong-term outcomesInfluence processesInjection drug usersHIV prevention interventionsSelf-reported behavioral outcomesHealth-related behaviorsLogistic regression modelsALIVE studyExperimental study designSeronegative participantsHIV preventionBaseline interviewPrevention interventionsEpidemiological studiesSignificant negative associationDrug usersPreventive interventionsExistence and Failure of T-Cell Homeostasis Prior to AIDS Onset in HIV-Infected Injection Drug Users
Galai N, Margolick J, Astemborski J, Vlahov D. Existence and Failure of T-Cell Homeostasis Prior to AIDS Onset in HIV-Infected Injection Drug Users. Clinical Immunology 1996, 79: 134-141. PMID: 8620619, DOI: 10.1006/clin.1996.0060.Peer-Reviewed Original ResearchConceptsInjection drug usersTotal T cellsT cell homeostasisT cellsHIV infectionAIDS onsetAIDS diagnosisHomosexual menDrug usersCurrent injection drug useSeropositive injection drug usersInjection drug useT cell levelsImportant prognostic valueALIVE studyClinic visitsPrognostic valueRisk groupsT lymphocytesAIDS casesLate failureDrug useHIVAIDSMonths
1995
Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A
Vlahov D, Khabbaz R, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 9: 89-96. PMID: 7712239, DOI: 10.1097/00042560-199505010-00013.Peer-Reviewed Original ResearchConceptsRisk factorsDrug usersEnzyme immunoassayWestern blotHuman T-lymphotropic virusNeedle-sharing practicesRisk factor analysisT-lymphotropic virusMedian lag timeCase-control designALIVE studyRecent serumSeronegative IDUsStudy entryBaseline historyIncidence rateSeroconversionPositive casesSex partnersIDUsHTLVCalendar timeMonthsIncidenceBaseline
1994
Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users
Aylward R, Vlahov D, Muñoz A, Rapiti E. Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users. AIDS 1994, 8: 1129-1134. PMID: 7986411, DOI: 10.1097/00002030-199408000-00015.Peer-Reviewed Original ResearchConceptsIntravenous drug usersClinical stage 1Proportional hazards modelStaging systemProduct limit estimatesWorld Health OrganizationALIVE studyHIV diseaseHazards modelPopulation of IVDUWorld Health Organization (WHO) staging systemDrug usersCox proportional hazards modelStage 1WHO staging systemTime of progressionStage 2Index visitHIV seropositivityHIV-seropositivePrognostic utilityClinical stageClinical criteriaOriginal cohortClinical signs
1991
The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods
Vlahov D, Anthony J, Muñoz A, Margolick J, Nelson K, Celentano D, Solomon L, Polk B. The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods. Journal Of Drug Issues 1991, 21: 759-776. DOI: 10.1177/002204269102100406.Peer-Reviewed Original ResearchIntravenous drug usersHuman immunodeficiency virusDrug usersConfidential HIV testingHIV-1 infectionMonths of recruitmentALIVE studyHIV testingImmunodeficiency syndromeImmunodeficiency virusRisk factorsExtensive community outreachLongitudinal studyInfectionCommunity outreachBaltimore MarylandPercentSyndromeCohortRecruitmentProgressionMonthsThe ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants.
Vlahov D, Anthony J, Munoz A, Margolick J, Nelson K, Celentano D, Solomon L, Polk B. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Research Monograph 1991, 109: 75-100. PMID: 1661376.Peer-Reviewed Original Research